中医药作为我国独特的卫生资源、潜力巨大的经济资源、具有原创优势的科技资源、优秀的文化资源和重要的生态资源，在服务贸易领域具有独特优势和发 展潜力。 9月11日，由北京市中医药管理局、北京市人民政府侨务办公室主办，世界中医药学会联合会、世界针灸学会联合会承办的"中医药主题日启动仪式暨第十届 海外华侨华人中医药大会"在首钢园修理车间举行。本次大会以"中医服务·惠通天下"为主题，全面呈现海内外中医药人在过去一年里，在服务贸易、标准制 定、数智中医等领域取得的突破性进展。 商务部服务贸易和商贸服务业司二级巡视员朱光耀在发言中针对中医药服务贸易提出四点建议。第一，加强平台载体建设，鼓励中医药企业利用境内外展会 平台推介优质产品服务，加快中医药产业国际化布局和品牌建设。第二，深化国际交流合作，推动中医药产品服务标准国际对接，加强海外中医药市场准 入、法律法规、行业管理等方面的沟通与协作。第三，推动中医药与文化贸易融合发展，积极推动中医药与文化创意、数字技术深度融合，鼓励打造具有中 国特色的健康服务品牌。第四，推动中医药服务贸易人才培养、引进和激励机制持续完善，加强复合型、国际化人才储备。 华侨华人是中医药国际化的"桥梁纽 ...

Group 1 - The 2025 China International Service Trade Fair (CIFTIS) showcased products like the "review chair" and "gift bag" from the 93rd National Day Parade, attracting significant attention from attendees [1][3] - The "gift bag" features advanced technology, including custom nylon material and innovative eco-friendly composite processes, designed by a professional team from Beijing Institute of Fashion Technology [3] - The "electrolyte drink" version of traditional sour plum soup, developed by Tongrentang, was launched at the fair, highlighting its unique ingredients and health benefits [6][8] Group 2 - The sour plum soup is made from selected ingredients such as black plum, hawthorn, dried tangerine peel, licorice, and honey, and is free from sugar, colorants, and artificial flavors [6] - The product combines traditional recipes with modern health concepts, incorporating sodium citrate, potassium chloride, and vitamin C to provide energy and electrolytes [6] - The fair featured 1,508 review chairs, which were used for service and support, allowing visitors to experience the ambiance of the National Day Parade [8]

根据《中华人民共和国公司法》《北京同仁堂股份有限公司章程》（以下简称《公司章程》）等有关规 定，北京同仁堂股份有限公司（以下简称公司或本公司）于2025年9月9日召开第三届第一次职工代表大 会，会议采取无记名投票方式，选举王继雄先生（简历附后）为公司第十届董事会职工代表董事，任期 至公司第十届董事会届满之日止。 截至本公告披露日，王继雄先生未持有公司股份，不存在法律法规、规范性文件以及《公司章程》规定 的不得担任公司董事的情形，不存在受到中国证券监督管理委员会行政处罚和证券交易所惩戒的情形， 不存在上海证券交易所认定的不适合担任上市公司董事的其他情况。 特此公告。 北京同仁堂股份有限公司董事会 2025年9月10日 证券代码：600085 证券简称：同仁堂 公告编号：2025-029 北京同仁堂股份有限公司 关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ...

证券日报网讯 9月9日晚间，同仁堂发布公告称，选举王继雄先生为公司第十届董事会职工代表董事。 （文章来源：证券日报） ...

截至本公告披露日，王继雄先生未持有公司股份，不存在法律法规、规范性 文件以及《公司章程》规定的不得担任公司董事的情形，不存在受到中国证券监 督管理委员会行政处罚和证券交易所惩戒的情形，不存在上海证券交易所认定的 不适合担任上市公司董事的其他情况。 特此公告。 北京同仁堂股份有限公司董事会 2025 年 9 月 10 日 北京同仁堂股份有限公司 关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《中华人民共和国公司法》《北京同仁堂股份有限公司章程》（以下简称 《公司章程》）等有关规定，北京同仁堂股份有限公司（以下简称公司或本公司） 于 2025 年 9 月 9 日召开第三届第一次职工代表大会，会议采取无记名投票方式， 选举王继雄先生（简历附后）为公司第十届董事会职工代表董事，任期至公司第 十届董事会届满之日止。 证券代码：600085 证券简称：同仁堂 公告编号：2025-029 附件： 王继雄先生，1984 年出生，研究生学历，政工师。曾任中国北京同仁堂（集 团）有限责任公司综合办公室（督查办公室 ...

Core Viewpoint - The traditional Chinese medicine (TCM) industry is experiencing structural opportunities amid policy promotion, price adjustments, technological innovations, and differentiated demand, with mixed performance among leading companies in the sector [1] Revenue and Profit Analysis - Yunnan Baiyao achieved both revenue and net profit growth, reporting revenue of 21.257 billion yuan, up 3.92%, and a net profit of 3.633 billion yuan, up 13.93%, marking a historical high for the period [2][6] - In contrast, Pizhou Huang experienced declines in both revenue and net profit, with revenue of 5.379 billion yuan, down 4.81%, and a net profit of 1.442 billion yuan, down 16.22%, marking its first revenue decline since its listing in 2003 [2][6] - Other companies like Huayuan Sanjiu, Tongrentang, and Baiyunshan reported revenue growth without corresponding profit increases, with Baiyunshan's revenue at 41.835 billion yuan, up 1.93%, but net profit down 1.31% to 2.516 billion yuan [2][8] Industry Trends - The TCM industry is transitioning from resource dependence to quality orientation, with enhanced quality control of medicinal materials [3] - The industry is undergoing deep price adjustments, with supply chains facing both pressure and restructuring, leading to a differentiated pricing landscape for medicinal materials [3] Innovation and R&D Focus - Innovation is emphasized as a core driver for growth in the pharmaceutical industry, with major TCM companies focusing on various aspects of research and development [10] - Yunnan Baiyao is actively pursuing projects in innovative drug development and has over 160 ongoing projects, including several innovative drugs in clinical trials [10][11] - Huayuan Sanjiu has increased its R&D investment by 68.99% to 662 million yuan, with a total of 205 projects in progress, following its acquisition of a 28% stake in Tian Shili [11] Future Outlook - The ability of these companies to convert their strategic innovations and R&D efforts into performance growth remains to be seen, with expectations for future developments in the TCM sector [12]

Core Viewpoint - The traditional Chinese medicine (TCM) industry is experiencing structural opportunities driven by policy support, price adjustments, technological innovations, and differentiated demand in the first half of 2025, with notable performance disparities among leading companies [1][3]. Group 1: Company Performance - Yunnan Baiyao achieved revenue of 212.57 billion yuan, a year-on-year increase of 3.92%, and a net profit of 36.33 billion yuan, up 13.93%, marking a historical high for the period [2][4]. - Baiyun Mountain reported revenue growth of 1.93% to 418.35 billion yuan, but net profit fell by 1.31% to 25.16 billion yuan [5][6]. - Huaren Sanjiu's revenue increased by 4.99% to 148.10 billion yuan, while net profit dropped significantly by 24.31% to 18.15 billion yuan [6][10]. - Tongrentang's revenue was 97.69 billion yuan, a slight increase of 0.06%, but net profit decreased by 7.39% to 9.45 billion yuan [5][6]. - Pianzaihuang experienced a revenue decline of 4.81% to 53.79 billion yuan and a net profit drop of 16.22% to 14.42 billion yuan, marking its first revenue decline since its listing in 2003 [4][5]. Group 2: Industry Trends - The TCM industry is transitioning from resource dependence to quality orientation, with enhanced quality control of medicinal materials [3][4]. - The industry is undergoing deep price adjustments, with supply chain pressures and restructuring, leading to a differentiated pricing landscape [3][4]. - The normalization of centralized procurement is accelerating market differentiation within the industry [3]. Group 3: Research and Innovation - Companies are emphasizing innovation as a core driver for growth, with Baiyun Mountain focusing on innovative drugs, generic drug consistency evaluation, and product redevelopment [7][10]. - Pianzaihuang is advancing multiple new drug projects, including 18 research projects and several clinical studies [8]. - Huaren Sanjiu has increased its R&D investment by 68.99% to 6.62 billion yuan, with 205 projects in progress following its acquisition of a 28% stake in Tian Shili [10][11]. - Yunnan Baiyao is integrating AI technologies across its operations, aiming for a digital transformation that enhances efficiency [9].

Summary of Key Points Core Viewpoint - A total of 135 stocks received buy ratings from institutions today, with 17 stocks receiving initial attention from institutions, indicating a strong interest in the market and potential investment opportunities [1]. Institutional Ratings - 140 buy rating records were published today, with 29 of these providing future target prices. 13 stocks have an upside potential exceeding 20%, with AVIC Optoelectronics showing the highest potential at 61.62% [1]. - Notable stocks with high upside potential include Noli Shares at 48.46% and United Imaging Healthcare at 37.22% [1]. - 17 stocks received initial buy ratings from institutions, including Haimeixing and Hengli Hydraulic [1]. Market Performance - Stocks rated with buy ratings saw an average increase of 3.27%, outperforming the Shanghai Composite Index. 119 stocks experienced price increases, with several hitting the daily limit up [1]. - Stocks with significant declines included Noli Shares, Agricultural Bank, and Shoufang Environmental Protection, with declines of 3.23%, 2.93%, and 1.26% respectively [1]. Industry Focus - The most favored industries include power equipment and machinery, each with 17 stocks listed in the buy rating category. The pharmaceutical and communication sectors also attracted attention, with 15 and 6 stocks respectively [2]. - Specific stocks receiving multiple buy ratings include Betaini, Kebo Da, AVIC Optoelectronics, and Yunnan Baiyao, each with two buy ratings [2][3]. Detailed Stock Information - A selection of stocks with buy ratings includes: - Betaini (2 ratings, +2.22% today, PE 40.30) in beauty care - Kebo Da (2 ratings, +10.00% today, PE 27.44) in automotive - AVIC Optoelectronics (2 ratings, +0.57% today, PE 28.83) in defense and military [2][3]. - Other notable stocks include: - Yunnan Baiyao (2 ratings, +1.06% today, PE 14.56) in pharmaceuticals - Zhonglian Heavy Industry (2 ratings, +0.41% today, PE 11.39) in machinery [2][3]. Additional Stock Ratings - Additional stocks with single buy ratings include: - Xuji Electric (1 rating, +2.09% today, PE 18.44) in power equipment - Xugong Machinery (1 rating, -0.20% today, PE 13.29) in machinery - China Rare Earth (1 rating, +2.33% today, PE 174.07) in non-ferrous metals [3][4].

Group 1 - The core point of the article is the announcement of leadership changes at Tong Ren Tang Guo Yao (03613.HK) due to the retirement of Gu Haiou [1] - Gu Haiou will retire as Executive Director, Chairman of the Board, and Authorized Representative effective September 4, 2025 [1] - Yan Han has been appointed as the new Chairman of the Board, while Le Zheng has been appointed as the Authorized Representative, both effective from the same date [1]

Group 1 - The announcement states that Gu Haiou will retire from his positions as Executive Director, Chairman of the Board, and Authorized Representative effective September 4, 2025, due to reaching retirement age [1] - Yan Han, currently an Executive Director, has been appointed as the new Chairman of the Board, effective September 4, 2025 [1] - Le Zheng, also an Executive Director and Vice Chairman, has been appointed as the Authorized Representative, effective September 4, 2025 [1]